重组促红细胞生成素在贫血癌症患者中的临床应用。
Clinical application of recombinant erythropoietin in anemic cancer patients.
作者信息
Henry D H
机构信息
Department of Medicine, University of Pennsylvania School of Medicine, Graduate Hospital Division of Hematology/Oncology, Philadelphia.
出版信息
Hematol Oncol Clin North Am. 1994 Oct;8(5):961-73.
PMID:7852218
Abstract
Anemia is common in cancer patients and may require treatment for symptomatic palliation. Transfusion has been the mainstay of therapy, but is not without risk. Because erythropoietin levels in cancer-related anemia are inadequate for the degree of anemia, recombinant human erythropoietin has been studied to treat the anemia. Results from these studies are encouraging.
摘要
贫血在癌症患者中很常见，可能需要进行治疗以缓解症状。输血一直是主要的治疗方法，但并非没有风险。由于癌症相关性贫血患者的促红细胞生成素水平不足以应对贫血程度，因此人们对重组人促红细胞生成素治疗贫血进行了研究。这些研究结果令人鼓舞。
Zotero 插件